Skip to Content
Search Menu

Ibrutinib, Lenalidomide, and Rituximab in Relapsed Mantle Cell Lymphoma

This study on long-term follow-up in relapsed mantle cell lymphoma involved a combination of lenalidomide, rituximab, and ibrutinib. Conducted in the Nordic countries, it showed a median progression-free survival of 70.4 months, even in TP53 mutated cases. Elin Forsgren, Uppsala University, presents the study in this MEDtalk at EHA 2024.
Elin Forsgren

Get access

If you are a doctor or other health professional, you can access the entire article by creating a profile on BestPractice Nordic.

Relateret indhold

Fredrik Schjesvold

ASH 2024 Highlights: Early Smouldering Myeloma Treatment and Breakthrough Therapies in Multiple Myeloma Take Center Stage

/ Fredrik Schjesvold
ASH24Myeloma Play the Video 02:57
Alex Lesokhin

Elranatamab Demonstrates Sustained Efficacy with Reduced Dosing Frequency in Refractory Multiple Myeloma

/ Alexander Lesokhin
ASH24Myeloma Play the Video 4:45

The Aquila Study Strongly Supports the Benefit of Early Intervention with Daratumumab Monotherapy in Patients with High-Risk Smoldering Multiple Myeloma

/ Jan Andreasen
ASH24Myeloma
Fredrik Schjesvold

The Trispecific Antibody SAR’257 Discontinued After Phase 1 Findings

/ Fredrik Schjesvold
ASH24Myeloma Play the Video 03:29

Several Trials Showed Improvements in the Treatment of Multiple Myeloma

/ BestPractice Nordic
EHA24Myeloma

EHA 2024: One of the Most Important for Many Years

/ BestPractice Nordic
EHA24Lymphoma

CLL: Needs At Least 10 Years of Follow-Up for Clinical Trials

/ BestPractice Nordic
CLLEHA24

The Development of New Treatment Options within AML Is Slower Than in Other Disease Areas within Hematology

/ BestPractice Nordic
AMLEHA24

New Data from EHA Shared and Discussed at Danish Evening

/ Jan Andreasen
EHA24
Back to top